Lecture. PSYCHOTROPIC DRUGS I. NEUROLEPTICS
... Corvalolum is mixture for oral administration, which is dosed by drops and contains ethylic ester of bromine-isovalerianic acid, 2% of phenobarbital, 3% of oil of menthe, sodium hydroxide, alcohol and water. It has sedative, spasmolytic and light hypnotic action and is used in neuroses, spasms of co ...
... Corvalolum is mixture for oral administration, which is dosed by drops and contains ethylic ester of bromine-isovalerianic acid, 2% of phenobarbital, 3% of oil of menthe, sodium hydroxide, alcohol and water. It has sedative, spasmolytic and light hypnotic action and is used in neuroses, spasms of co ...
Pharmacologic Control of Vomiting
... Pharmacologic Control of Acute Vomiting Initial nonspecific management of vomiting includes NPO (in minor cases a 6-12 hour period of nothing per os may be all that is required), fluid support, and antiemetics. Initial feeding includes small portions of a low fat, single source protein diet starting ...
... Pharmacologic Control of Acute Vomiting Initial nonspecific management of vomiting includes NPO (in minor cases a 6-12 hour period of nothing per os may be all that is required), fluid support, and antiemetics. Initial feeding includes small portions of a low fat, single source protein diet starting ...
3rd year antidepressant part 2a2011-09-11 10
... 5-HT1-receptors are predominantly inhibitory in their effects. 5-HT1A-receptors are expressed as autoreceptors by the 5-HT neurons in the raphe nuclei, and their autoinhibitory effect tends to limit the rate of firing of these cells. They are also widely distributed in the limbic system and are bel ...
... 5-HT1-receptors are predominantly inhibitory in their effects. 5-HT1A-receptors are expressed as autoreceptors by the 5-HT neurons in the raphe nuclei, and their autoinhibitory effect tends to limit the rate of firing of these cells. They are also widely distributed in the limbic system and are bel ...
antiparkinsonian drugs
... Two types of monoamine oxidase (MAO) have been distinguished. Monoamine oxidase (A) metabolizes norepinephrine and serotonin,dopamine; monoamine oxidase (B) metabolizes dopamine selectively. Selegiline (deprenyl) and rasagiline: Mechanism of action: • Selective irreversible inhibitors of monoamine o ...
... Two types of monoamine oxidase (MAO) have been distinguished. Monoamine oxidase (A) metabolizes norepinephrine and serotonin,dopamine; monoamine oxidase (B) metabolizes dopamine selectively. Selegiline (deprenyl) and rasagiline: Mechanism of action: • Selective irreversible inhibitors of monoamine o ...
Rapid tranquillisation - The British Journal of Psychiatry
... sheet, Lundbeck), and the number of times the drug can be administered (four injections or 400 mg; British Medical Association & Royal Pharmaceutical Society of Great Britain, 2000). Further, sudden deaths and fatal cardiac events have been reported to the Medicines Control Agency (MCA) of the UK wi ...
... sheet, Lundbeck), and the number of times the drug can be administered (four injections or 400 mg; British Medical Association & Royal Pharmaceutical Society of Great Britain, 2000). Further, sudden deaths and fatal cardiac events have been reported to the Medicines Control Agency (MCA) of the UK wi ...
PCF Guidelines: Palliative sedation in the imminently dying
... If the patient is rational, the drug of choice is midazolam (or other benzodiazepine). If an agitated delirium, prescribe an antipsychotic (e.g. haloperidol) ± midazolam. If necessary, replace haloperidol with levomepromazine (much more sedative) If levomepromazine + midazolam fail to relieve, repla ...
... If the patient is rational, the drug of choice is midazolam (or other benzodiazepine). If an agitated delirium, prescribe an antipsychotic (e.g. haloperidol) ± midazolam. If necessary, replace haloperidol with levomepromazine (much more sedative) If levomepromazine + midazolam fail to relieve, repla ...
![Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)](http://s1.studyres.com/store/data/008004324_1-4687ab11684bc08b6291bceb18fec16a-300x300.png)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
... abnormal posture (dystonia). At dosages greater than 10 mg/day, some patients may experience akathisia, which is a subjective feeling of restlessness accompanied by fidgeting, pacing, or inability to sit still. EPS may be managed by decreasing the antipsychotic dosage or adding another medication (a ...
... abnormal posture (dystonia). At dosages greater than 10 mg/day, some patients may experience akathisia, which is a subjective feeling of restlessness accompanied by fidgeting, pacing, or inability to sit still. EPS may be managed by decreasing the antipsychotic dosage or adding another medication (a ...
6-作用于神经系统的药物
... ①Only treat to acute megalgia(急性剧痛), such as severe wound, large area of burn, etc. The aim is to prevent painful shock, but contraindication for shock. ②Treat to pain of later period of cancer ...
... ①Only treat to acute megalgia(急性剧痛), such as severe wound, large area of burn, etc. The aim is to prevent painful shock, but contraindication for shock. ②Treat to pain of later period of cancer ...
Simon Chiu and others(1981)11dec7
... roperidol binding pro- behavioral and biochemical ntanifestatives should be considered as potential duced by long-term administration of lions of neuroleptic-induced dopaminerprophylactic and therapeutic agents in neuroleptics alone. Striata from rats gic supersensitivity have been found to the clin ...
... roperidol binding pro- behavioral and biochemical ntanifestatives should be considered as potential duced by long-term administration of lions of neuroleptic-induced dopaminerprophylactic and therapeutic agents in neuroleptics alone. Striata from rats gic supersensitivity have been found to the clin ...
Alpha Receptors, Beta Receptors, Kappa Receptors
... • Not only stimulates nicotinic receptors, it also triggers the release of endorphins and dopamine in the mesolimbic system of the brain • Pleasure, addiction and reward are the result • Also inhibitory transmitters are released, such as GABA, to reduce anxiety, lessening of irritation and aggressio ...
... • Not only stimulates nicotinic receptors, it also triggers the release of endorphins and dopamine in the mesolimbic system of the brain • Pleasure, addiction and reward are the result • Also inhibitory transmitters are released, such as GABA, to reduce anxiety, lessening of irritation and aggressio ...
Serex Film Coated Tablets 25-100-200-300 mg, 30 tablets
... for deterioration in glucose table. Quetiapine may cause dizziness, tachycardia and sometimes hypotension accompanied by syncope, especially in dose increasing period at the start of treatment. As in with other antipsychotics, quetiapine also should be used carefully in patients that have seizures o ...
... for deterioration in glucose table. Quetiapine may cause dizziness, tachycardia and sometimes hypotension accompanied by syncope, especially in dose increasing period at the start of treatment. As in with other antipsychotics, quetiapine also should be used carefully in patients that have seizures o ...
ATYPICAL ANTIPSYCHOTIC
... are antagonists of D2 and serotonin 2A receptors, but they can affect many other types of receptors. Atypical antipsychotics: D2 receptor blockade of postsynaptic in the mesolimbic pathway reduce positive symptoms enhanced dopamine release and 5-HT2A receptor blockade in the mesocortical pathway ...
... are antagonists of D2 and serotonin 2A receptors, but they can affect many other types of receptors. Atypical antipsychotics: D2 receptor blockade of postsynaptic in the mesolimbic pathway reduce positive symptoms enhanced dopamine release and 5-HT2A receptor blockade in the mesocortical pathway ...
Restless legs syndrome (RLS): Diagnosis
... degeneration of dopaminergic neurones (exception A11 degeneration?), hence small doses of L-DOPA may cause an overflow of dopamine. ...
... degeneration of dopaminergic neurones (exception A11 degeneration?), hence small doses of L-DOPA may cause an overflow of dopamine. ...
File
... • Is a semisynthetic ergot derivative of ergoline, a dopamine D2receptor agonist with agonist and antagonistic properties on D1 receptors. • Because of its short half-life (3.3 hours), bromocriptine may require multiple dosing throughout the day. • Approximately 12 % of patients are unable to tolera ...
... • Is a semisynthetic ergot derivative of ergoline, a dopamine D2receptor agonist with agonist and antagonistic properties on D1 receptors. • Because of its short half-life (3.3 hours), bromocriptine may require multiple dosing throughout the day. • Approximately 12 % of patients are unable to tolera ...
Practice Debate
... Practical conclusions: antipsychotics in the treatment of BPSD Both conventional and atypical agents may be effective in patients with BPSD who have psychotic type features, aggression or potential for harm. There is no clear evidence that atypical antipsychotics are more likely to cause CVAE than c ...
... Practical conclusions: antipsychotics in the treatment of BPSD Both conventional and atypical agents may be effective in patients with BPSD who have psychotic type features, aggression or potential for harm. There is no clear evidence that atypical antipsychotics are more likely to cause CVAE than c ...
Antiemetic drugs
... • Neurokinin 1 (NK1) receptor antagonist on nucleus of tractus solitaries and Visceral afferent nerves • So it prevent both peripheral and central stimulation of the vomiting center Uses as antiemetic: • In combination with 5-HT3 blockers to treat vomiting due to cancer chemotherapy Adverse effects: ...
... • Neurokinin 1 (NK1) receptor antagonist on nucleus of tractus solitaries and Visceral afferent nerves • So it prevent both peripheral and central stimulation of the vomiting center Uses as antiemetic: • In combination with 5-HT3 blockers to treat vomiting due to cancer chemotherapy Adverse effects: ...
Child Psychiatric Medications 101
... • the effects of all drugs are dose‐dependent – the amount of drug that is administered determines both qualitative and quantitative aspects of its effects – very low doses ‐ no observable effects – high enough doses ‐ toxic reactions ...
... • the effects of all drugs are dose‐dependent – the amount of drug that is administered determines both qualitative and quantitative aspects of its effects – very low doses ‐ no observable effects – high enough doses ‐ toxic reactions ...
Dopamine Hypothesis of Mania
... One of the supports of this hypothesis was the effect of amphetamines which release catecholamines. Low doses of amphetamines produce a state resembling mild mania but with reduced hunger and appetite and anomalous endocrine effects (7). Dopamine agonists, such as bromocriptine, used to treat pr ...
... One of the supports of this hypothesis was the effect of amphetamines which release catecholamines. Low doses of amphetamines produce a state resembling mild mania but with reduced hunger and appetite and anomalous endocrine effects (7). Dopamine agonists, such as bromocriptine, used to treat pr ...
L10-Parkinsonism
... (A) It should not be administered to patients taking antimuscarinic drugs (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients alr ...
... (A) It should not be administered to patients taking antimuscarinic drugs (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients alr ...
Parkinsonism-b
... (A) It should not be administered to patients taking antimuscarinic drugs (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients alr ...
... (A) It should not be administered to patients taking antimuscarinic drugs (B) Effectiveness in Parkinson's disease requires its metabolic conversion to an active metabolite (C) The drug is contraindicated in patients with a history of psychosis (D) The drug should not be administered to patients alr ...
Slide 1
... If schizophrenia is merely an increase in dopamine, drugs should work right away 2.Not all schizophrenic patients respond to drugs that block dopamine receptors If schizophrenia is merely an increase in dopamine, drugs should work for all patients 3.Dopamine blockers can alleviate psychosis, but do ...
... If schizophrenia is merely an increase in dopamine, drugs should work right away 2.Not all schizophrenic patients respond to drugs that block dopamine receptors If schizophrenia is merely an increase in dopamine, drugs should work for all patients 3.Dopamine blockers can alleviate psychosis, but do ...
Gill Kerr agranulocyoctosis
... Atypical antipsychotic drugs differ from traditional antipsychotic agents in their ability to act as dopamine receptor and serotonin receptor blockers. This simultaneous blocking may account for the increased efficacy of these drugs in improving the negative symptoms of schizophrenia. ...
... Atypical antipsychotic drugs differ from traditional antipsychotic agents in their ability to act as dopamine receptor and serotonin receptor blockers. This simultaneous blocking may account for the increased efficacy of these drugs in improving the negative symptoms of schizophrenia. ...
psych medications
... • Other Adverse effects – Prolactinemia • D2 receptor blockade decreases dopamine inhibition of prolactin • Results in galactorrhea, amenorrhea, loss of libido – Managed with bromocriptine ...
... • Other Adverse effects – Prolactinemia • D2 receptor blockade decreases dopamine inhibition of prolactin • Results in galactorrhea, amenorrhea, loss of libido – Managed with bromocriptine ...
Chlorpromazine
Chlorpromazine (CPZ) — marketed as Thorazine among others — is a dopamine antagonist of the typical anti-psychotic class of medications possessing additional antiadrenergic, anti-serotonergic, anticholinergic and antihistaminergic properties used to treat schizophrenia. First synthesized on December 11, 1951, chlorpromazine was the first drug developed with specific antipsychotic action and would serve as the prototype for the phenothiazine class of drugs, which comprises several other agents. The introduction of chlorpromazine during the 1950s has been described as the single greatest advance in the history of psychiatric care, improving the prognosis of people in psychiatric hospitals.Chlorpromazine works on a variety of receptors in the central nervous system, producing potent anticholinergic, antidopaminergic, antihistaminic, and antiadrenergic effects. Both the clinical indications and side effect profile of CPZ are determined by the broadness of its action: its anticholinergic properties cause constipation, sedation, and hypotension but also help relieve nausea. It also has anxiolytic (anxiety-relieving) properties. Its antidopaminergic properties can cause extrapyramidal symptoms, such as akathisia (restlessness, where the patient walks almost constantly, despite having nowhere to go due to mandatory confinement) and dystonia. It is known to cause tardive dyskinesia, which can be irreversible. In acute settings, it is often administered as a syrup, which has a faster onset of action than tablets, and it can also be given by intramuscular injection. IV administration is very irritating and is not advised; its use is limited to severe hiccups, surgery, and tetanus.Chlorpromazine is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.